• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Sherman Biotech Plans Studies and Clinical Trials for Treatment of Anxiety Associated With Fragile X Syndrome, Autism

Posted on: Tuesday, 17 October 2006, 18:01 CDT

Sherman Biotech Inc., a wholly-owned subsidiary of Early Detect, Inc., announced today that it has scheduled seminars this fall in Chicago, Boston and New York City to discuss the company's plans to begin preclinical studies and clinical trials of SB15, a newly-formulated compound for the treatment of anxiety associated with fragile X syndrome and autism. SB15 shows promise as an alternative to current drug therapies, such as stimulants, antidepressants and anticonvulsants that broadly suppress anxiety in individuals with these conditions. "Our research shows that the formulated version of SB15 could have therapeutic benefits for anxiety in appropriate patients," said Dr. David Schwartz, Sherman Biotech's chief science officer.

Charles Strongo, Early Detect's chief executive officer, states, "Early Detect and its subsidiaries are committed to finding more effective treatments for such serious conditions as autism and Fragile X. Autism is clearly on the rise around the world, and anyone who has been touched by this disability understands the difficulties associated with finding effective treatment therapies."

At the seminars, Early Detect and Sherman Biotech executives will discuss preliminary animal studies that indicate SB15 has only mild side effects and is highly effective as a potential treatment. They will also discuss the company's plans to finance the development of the therapy as a candidate through preclinical toxicity studies, followed by human clinical trials. All interested parties are encouraged to attend the informational seminars. For the details of locations and times, call Kevin Miller at 517-482-3624.

About Sherman Biotech Inc.

Sherman Biotech Inc. is an early-stage company specializing in the development of pharmaceutical compounds for the specific treatment of anxiety in the inherited disorder known as fragile X and in related conditions such as autism. Sherman Biotech is also conducting research to create diagnostic tests for these conditions.

About Early Detect Inc.

Early Detect, Inc., was founded in 1996 with the mission of empowering individuals to take control of their health and healthcare. The only company to have a single-branded, comprehensive line of home health test kits, Early Detect is committed to providing safe and effective health tests for both consumers and the medical community. Early Detect and its subsidiaries, Sherman Biotech and PanProbe, strive to develop and successfully market treatments and detection tests that improve overall health and well-being.

This release has been prepared solely for the information of the recipient, and may not be used for any other purpose. Some of the statements in this release may constitute forward-looking statements, since such statements relate to matters which have not yet occurred, and have been prepared on the basis of assumptions and hypotheses deemed appropriate by the companies. Future operating results are impossible to predict and no representations can be or are being made with respect to the future accuracy or completeness of any forecasts or projections. This release does not constitute an offer or solicitation for the sale or purchase of securities. Any offering for the sale or purchase of securities involves a high degree of risk. Potential investors are expected to make their own investigation and to consult with their own advisors and counsel as to the consequences of an investment.

Source: Business Wire

More News in this Category